Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice

Background: Etanercept is well tolerated and effective in moderate to severe psoriasis; however, data on patient-reported outcomes (PROs) in Canadian patients remain limited. Objective: To assess PROs in Canadian patients with moderate to severe psoriasis receiving etanercept in an open-label trial more representative of general clinical practice than traditional research studies. Methods: This 1-year, multicenter, single-arm study enrolled 246 patients. Patients received etanercept 50 mg subcutaneously twice weekly for 3 months and then 50 mg once weekly for 9 months. Primary and safety end points were reported previously. Change from baseline to month 12 for the Dermatology Life Quality Index (DLQI), EuroQoL-5D, and Treatment Satisfaction Questionnaire for Medication (TSQM) are secondary outcomes reported here. Post hoc analyses of PROs are also reported. Results: Mean 6 standard deviation (SD) DLQI total score improved from 13.7 +/- 6.1 at baseline to 3.9 +/- 5.6 at month 12. By month 12, 75% of patients achieved a clinically meaningful improvement in the DLQI (>= 5-point improvement or a score of 0). Fifty-three to 86% of patients reported improvement or complete improvement in the six DLQI subscales. The mean 6 SD EuroQoL-5D total score improved from baseline (0.67 +/- 0.25) to month 12 (0.83 +/- 0.25). The TSQM scores showed improvement in global satisfaction, effectiveness, and convenience after 3 months. Conclusions: Etanercept was associated with improved PROs and increased treatment satisfaction over 1 year.